{"id":75033,"date":"2025-03-27T00:18:33","date_gmt":"2025-03-26T23:18:33","guid":{"rendered":"https:\/\/www.infokuryr.cz\/n\/?p=75033"},"modified":"2025-03-26T16:29:03","modified_gmt":"2025-03-26T15:29:03","slug":"korejsti-vedci-tise-potvrzuji-nocni-muru-vakciny-covid","status":"publish","type":"post","link":"https:\/\/www.infokuryr.cz\/n\/2025\/03\/27\/korejsti-vedci-tise-potvrzuji-nocni-muru-vakciny-covid\/","title":{"rendered":"Korej\u0161t\u00ed v\u011bdci ti\u0161e potvrzuj\u00ed no\u010dn\u00ed m\u016fru vakc\u00edny COVID"},"content":{"rendered":"
<\/div>\n
\n
\n

\u00dadaje jsou k dispozici. To u\u017e nen\u00ed konspira\u010dn\u00ed teorie.<\/strong><\/h3>\n

Studie\u00a0s n\u00e1zvem\u00a0\u201e\u0160irokospektr\u00e1ln\u00ed ne\u017e\u00e1douc\u00ed p\u0159\u00edhody zvl\u00e1\u0161tn\u00edho z\u00e1jmu na z\u00e1klad\u011b imunitn\u00ed reakce po o\u010dkov\u00e1n\u00ed proti COVID-19: kohortov\u00e1 studie velk\u00e9ho rozsahu na z\u00e1klad\u011b populace\u201c\u00a0<\/strong>byla<\/a>\u00a0ned\u00e1vno zve\u0159ejn\u011bna v\u00a0Journal of Clinical Medicine<\/em>\u00a0:<\/p>\n

Pozad\u00ed \/ C\u00edl:<\/h3>\n

P\u0159edchoz\u00ed studie o vedlej\u0161\u00edch \u00fa\u010dinc\u00edch vakc\u00edn COVID-19 se zam\u011b\u0159ovaly p\u0159edev\u0161\u00edm na z\u00e1va\u017en\u00e9, \u017eivot ohro\u017euj\u00edc\u00ed vedlej\u0161\u00ed \u00fa\u010dinky. \u0158ada m\u00e9n\u011b z\u00e1va\u017en\u00fdch, ale b\u011b\u017en\u00fdch ne\u017e\u00e1douc\u00edch p\u0159\u00edhod (AE) v\u0161ak nebyla dostate\u010dn\u011b studov\u00e1na, i kdy\u017e mohou m\u00edt v\u00fdznamn\u00fd dopad.<\/p>\n

Metody:<\/h3>\n

Tato kohortov\u00e1 studie zalo\u017een\u00e1 na populaci zkoumala kumulativn\u00ed m\u00edru v\u00fdskytu (cIR) a riziko \u0161irok\u00e9ho spektra ne\u017e\u00e1douc\u00edch p\u0159\u00edhod zvl\u00e1\u0161tn\u00edho z\u00e1jmu (AESI), kter\u00e9 lze p\u0159ipsat imunitn\u00edm reakc\u00edm po o\u010dkov\u00e1n\u00ed proti COVID-19, v\u010detn\u011b gynekologick\u00fdch, dermatologick\u00fdch, oftalmologick\u00fdch, otologick\u00fdch a dent\u00e1ln\u00edch probl\u00e9m\u016f.<\/p>\n

V\u00fdsledky:<\/h3>\n

Z celkov\u00e9ho po\u010dtu\u00a04 203 887 lid\u00ed v Soulu v Ji\u017en\u00ed Koreji<\/strong>\u00a0bylo do kone\u010dn\u00e9 anal\u00fdzy zahrnuto\u00a01 458 557 o\u010dkovan\u00fdch<\/strong>\u00a0a\u00a0289 579 neo\u010dkovan\u00fdch<\/strong>\u00a0subjekt\u016f (po vylou\u010den\u00ed ji\u017e existuj\u00edc\u00edch onemocn\u011bn\u00ed) .<\/p>\n

CIR do t\u0159\u00ed m\u011bs\u00edc\u016f byla signifikantn\u011b vy\u0161\u0161\u00ed u o\u010dkovan\u00fdch ne\u017e u neo\u010dkovan\u00fdch \u2013 s v\u00fdjimkou endometri\u00f3zy.<\/p>\n

O\u010dkov\u00e1n\u00ed v\u00fdznamn\u011b zv\u00fd\u0161ilo riziko t\u00e9m\u011b\u0159 v\u0161ech AESI, krom\u011b poruch zraku.<\/p>\n

Nejvy\u0161\u0161\u00ed riziko bylo pozorov\u00e1no u\u00a0vypad\u00e1v\u00e1n\u00ed vlas\u016f<\/strong>\u00a0:<\/p>\n

Rizikov\u00e9 pom\u011bry (HR = Hazard Ratio):<\/h3>\n
    \n
  1. Vypad\u00e1v\u00e1n\u00ed vlas\u016f (alopecie)<\/strong>
    \n\ud83d\udd39\u00a0HR:\u00a02,40<\/strong>\u00a0(95% CI: 1,90\u20133,03)
    \n\u27a4 O\u010dkovan\u00ed jedinci byli\u00a0posti\u017eeni\u00a02,4kr\u00e1t \u010dast\u011bji .<\/strong><\/li>\n
  2. Poruchy vnit\u0159n\u00edho ucha (rovnov\u00e1ha\/sluch)<\/strong>
    \n\ud83d\udd39\u00a0HR:\u00a02,37<\/strong>\u00a0(95% CI: 2,15\u20132,60)<\/li>\n
  3. Herpes zoster (p\u00e1sov\u00fd opar)<\/strong>
    \n\ud83d\udd39\u00a0HR:\u00a02,34<\/strong>\u00a0(95% CI: 2,12\u20132,57)<\/li>\n
  4. Bradavice (virov\u00e9 ko\u017en\u00ed v\u00fdr\u016fstky)<\/strong>
    \n\ud83d\udd39\u00a0HR:\u00a02,20<\/strong>\u00a0(95% CI: 1,95\u20132,60)<\/li>\n
  5. Menstrua\u010dn\u00ed poruchy<\/strong>
    \n\ud83d\udd39\u00a0HR:\u00a02,16<\/strong>\u00a0(95% CI: 1,96\u20132,37)<\/li>\n
  6. Infekce\/probl\u00e9my st\u0159edn\u00edho ucha<\/strong>
    \n\ud83d\udd39\u00a0HR:\u00a02,08<\/strong>\u00a0(95% CI: 1,75\u20132,47)<\/li>\n
  7. Tinnitus (zvon\u011bn\u00ed v u\u0161\u00edch)<\/strong>
    \n\ud83d\udd39\u00a0HR:\u00a01,75<\/strong>\u00a0(95% CI: 1,50\u20132,20)<\/li>\n
  8. Parodontitida (onemocn\u011bn\u00ed d\u00e1sn\u00ed)<\/strong>
    \n\ud83d\udd39\u00a0HR:\u00a02,05<\/strong>\u00a0(95% CI: 1,45\u20133,00)<\/li>\n
  9. Glaukom (zelen\u00fd z\u00e1kal)<\/strong>
    \n\ud83d\udd39\u00a0HR:\u00a01,86<\/strong>\u00a0(95% CI: 1,66\u20132,09)<\/li>\n
  10. Mod\u0159iny (nebol\u00ed, na\u017eloutl\u00e9 zabarven\u00ed)<\/strong>
    \n\ud83d\udd39\u00a0HR:\u00a01,78<\/strong>\u00a0(95% CI: 1,27\u20132,49)<\/li>\n
  11. Endometri\u00f3za (bolest p\u00e1nve\/neplodnost)<\/strong>
    \n\ud83d\udd39\u00a0HR:\u00a01,50<\/strong>\u00a0(95% CI: 1,25\u20131,79)<\/li>\n
  12. Zrakov\u00e9 posti\u017een\u00ed (rozmazan\u00e9\/sn\u00ed\u017een\u00e9 vid\u011bn\u00ed)<\/strong>
    \n\ud83d\udd39\u00a0HR:\u00a03,94<\/strong>\u00a0(95% CI: 0,94\u201316,41) \u2013\u00a0nen\u00ed statisticky v\u00fdznamn\u00e9 kv\u016fli \u0161irok\u00e9mu intervalu spolehlivosti<\/em><\/li>\n<\/ol>\n

    Z\u00e1v\u011br:<\/h3>\n

    Studie nazna\u010duje, \u017ee\u00a0by l\u00e9ka\u0159i m\u011bli bedliv\u011b sledovat \u0161irokou \u0161k\u00e1lu vedlej\u0161\u00edch \u00fa\u010dink\u016f souvisej\u00edc\u00edch s vakc\u00ednou<\/strong>\u00a0\u2013 i kdy\u017e se zpo\u010d\u00e1tku zdaj\u00ed b\u00fdt nepatrn\u00e9.<\/p>\n

    D\u0159\u00edve podce\u0148ovan\u00e9 reakce \u2013 jako je vypad\u00e1v\u00e1n\u00ed vlas\u016f, probl\u00e9my s d\u00e1sn\u011bmi nebo tinitus \u2013 by mohly b\u00fdt\u00a0\u010dasn\u00fdmi indik\u00e1tory z\u00e1va\u017en\u00fdch syst\u00e9mov\u00fdch reakc\u00ed<\/strong>\u00a0. A\u010dkoli se tyto \u00fa\u010dinky nezdaj\u00ed b\u00fdt z\u00e1va\u017en\u00e9, mohly by b\u00fdt v\u00fdrazem hlub\u0161\u00edch dysfunkc\u00ed imunitn\u00edho syst\u00e9mu.<\/p>\n

    Posouzen\u00ed:<\/h3>\n

    Tato studie je jedn\u00edm z dosud nejkomplexn\u011bj\u0161\u00edch v\u00fdzkum\u016f \u0161irok\u00fdch vedlej\u0161\u00edch \u00fa\u010dink\u016f spojen\u00fdch s vakc\u00ednou. Ona prozrazuje:<\/p>\n